Motives for the use of serotonergic psychedelics: A systematic review
This systematic review of 37 studies found that serotonergic psychedelics are most commonly used to expand self‑awareness or spirituality (reported in 78% of studies), with coping (67%) and enhancement (57%) also frequent, and no consistent links to drug type, study method, year or user population. The authors suggest harm‑reduction services should offer non‑pharmacological ways to fulfil expansion motives and that future research examine motives for specific SPs.
Authors
- Basedow, L. A.
- Kuitunen-Paul, S.
Published
Abstract
IssuesSerotonergic psychedelics (SP) are psychoactive substances that produce unique sets of subjective effects, such as hallucinatory experiences. This systematic review is the first to summarise which motives for SP use have been assessed in medical, psychological, sociological and ethnological research across different types of SPs and across cultural backgrounds. Findings on use motives can be especially important in the context of harm reduction.ApproachWe searched academic databases (Medline, Web of Science and Embase) and included publications if they were peer‐reviewed and written in English, German, Spanish or Dutch. We analysed which type of motives were reported, comparing motives from quantitative and qualitative reports, and investigating associations between motives and year of publication, specific SPs and specific participant populations.Key FindingsOur search in November 2020 resulted in 30,257 unique articles of which 37 were included in the analysis. Across all studies, the most common motive for SP use was the desire to expand awareness (78% of included studies), followed by coping (67%) and enhancement (57%) motives. There were no statistically significant associations between reported motive and type of report (quantitative vs. qualitative), year of publication (range: 1967–2020), type of SP and participant population.
Implications
If SP‐related harms are to be reduced, harm‐reduction services could focus on providing non‐pharmacological ways of fulfilling an expansion motive. Additionally, future studies should aim to assess specific motives for specific SPs.
Conclusions
SPs are most commonly used to expand (self‐)knowledge, promote spiritual development or for curiosity, notably across different SP user populations including patients.
Research Summary of 'Motives for the use of serotonergic psychedelics: A systematic review'
Introduction
Psychoactive substances are used for many different reasons, and research on substance-use motives has developed models to explain why people use particular drugs. Based on motivational work in alcohol and cannabis research, a five-factor model of substance-use motives is often employed: social, conformity, coping, enhancement and expansion. The expansion motive—reflecting a wish to gain self-knowledge or alter perception—was added to capture motives more typical of substances with psychedelic properties. This review by Basedow and colleagues set out to fill a gap: no prior synthesised review had characterised motives for use specifically across the class of serotonergic psychedelics (SPs), which include tryptamines (for example psilocybin, DMT), ergolines (for example LSD) and phenethylamines (for example mescaline). The study aimed to summarise which motives have been assessed in the literature, compare findings from quantitative versus qualitative studies, and explore whether reported motives vary by year of publication, specific SPs, or participant populations. The investigators anticipated that qualitative and quantitative approaches might yield different frequencies of reported motives.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Topic
- APA Citation
Basedow, L. A., & Kuitunen‐Paul, S. (2022). Motives for the use of serotonergic psychedelics: A systematic review. Drug and Alcohol Review, 41(6), 1391-1403. https://doi.org/10.1111/dar.13480
References (20)
Papers cited by this study that are also in Blossom
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Nichols, D. E. · Current Topics in Behavioral Neurosciences (2017)
Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Müller, F., Holze, F., Becker, A. M. et al. · Psychopharmacology (2022)
Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)
Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)
Cakic, V., Potkonyak, J., Marshall, A. · Drug and Alcohol Dependence (2010)
Davis, A. K., Barsuglia, J. P., Lancelotta, R. et al. · Journal of Psychopharmacology (2018)
Show all 20 referencesShow fewer
Di Lorenzo, C., Di Lorenzo, G., Coppola, G. et al. · Cephalalgia (2015)
Kjellgren, A., Eriksson, A., Norlander, T. · Journal of Psychoactive Drugs (2009)
Kjellgren, A., Soussan, C. · Journal of Psychoactive Drugs (2011)
Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)
Webb, M., Copes, H., Hendricks, P. S. · International Journal of Drug Policy (2019)
Winkler, P., Csémy, L. · Journal of Psychoactive Drugs (2014)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)
Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)
Garcia-Romeu, A., Davis, A. K., Fire Erowid et al. · Journal of Psychopharmacology (2019)
Cited By (2)
Papers in Blossom that reference this study
Cherniak, A. D., Granqvist, P., Mikulincer, M. et al. · Journal of Psychoactive Drugs (2026)
Jiwani, Z., Goldberg, S. B., Stroud, J. et al. · MedRvix (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.